Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 8/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CALML3 | P27482 | 1/20 | 0.42 |
| ▸ | SDHA | P31040 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5386202 | 0.92 | F10 (0.46) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5388553 | 0.88 | MAOB (0.54) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5392340 | 0.85 | F10 (0.45) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5384341 | 0.85 | F10 (0.52) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL6097345 | 0.84 | F10 (0.55) | F10MAOBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14580127 | 0.83 | F10 (0.52) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5382251 | 0.83 | F10 (0.52) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5378513 | 0.83 | MAOA (0.62) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL14580150 | 0.81 | F10 (0.58) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5378737 | 0.81 | F10 (0.60) | F10MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030148-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2006-04-18 | — | — | US | claimed |
| US-20040059120-A1 | Novel heterocyclic compounds having antibacterial activity: Process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2004-03-25 | — | — | US | claimed |
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION | 2003-04-03 | — | — | US | claimed |
| US-7183301-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2007-02-27 | — | — | US | disclosed |
| US-7030148-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2006-04-18 | — | — | US | disclosed |
| US-20040059120-A1 | Novel heterocyclic compounds having antibacterial activity: Process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2004-03-25 | — | — | US | disclosed |
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | MRPL21, Q6ZSR9, ZYX | F10 1269/4885MAOB 364/4885MAOA 460/4885 |
| US-20040059120-A1 | Novel heterocyclic compounds having antibacterial activity: Process for their preparation and pharmaceutical compositions containing them | MRPL21, Q6ZSR9, ZYX | F10 1429/4885MAOB 348/4885MAOA 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.